Literature DB >> 24267733

Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up.

Sreekumar Sundara Rajan1, Rashmi Verma, Abeer M Shaaban, Nisha Sharma, Barbara Dall, Mark Lansdown.   

Abstract

BACKGROUND: Palpable pure DCIS is a rare entity that presents differently than screen-detected DCIS. The aim of this study was to evaluate the clinical, radiological, and pathological characteristics and management of pDCIS in a retrospective cohort of patients. PATIENTS AND METHODS: Patients diagnosed with pDCIS from January 1999 to December 2011 were identified from an electronic patient database and were included in this study.
RESULTS: During this period, 669 cases of DCIS were diagnosed and 62 (9.3%) were pDCIS (mean age, 56.9 ± 15.1 years). The most common finding on ultrasound was mass in 43 patients (75%) and only 18 (33%) cases had calcification on mammography. The lesion was mammographically occult in 20 patients (37%). Ultrasound was more sensitive and delineated the pDCIS in 45 (80%) cases. Mean size of the pDCIS was 36.9 ± 30.4 mm and most were high grade (n = 42; 68%) and associated with comedo necrosis in 36 (59%). Most were oestrogen receptor (ER)-positive (n = 34; 62%), however 21 patients (38%) were ER-negative. Breast conservation was attempted in 30 patients (48%), however, because of involved margins further therapeutic surgery was needed in 10 patients (33%). Axillary surgery (sentinel lymph node biopsy or axillary nodal sampling) was performed in 34 patients (55%) and no lymph node metastasis was identified. During a medial follow-up of 60 months, 1 patient has developed a mastectomy scar recurrence and the rest remain disease-free.
CONCLUSION: Palpable DCIS is often occult on conventional radiological imaging and is generally associated with aggressive pathological features. Hence, careful individualized surgical planning through a multidisciplinary meeting is necessary for their management.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histology; Intraductal; Noninfiltrating; Radiology; Therapeutic agents

Mesh:

Year:  2013        PMID: 24267733     DOI: 10.1016/j.clbc.2013.08.002

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  7 in total

1.  Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ.

Authors:  Ahmed Yahia Al-Ameer; Sahar Al Nefaie; Badria Al Johani; Ihab Anwar; Taher Al Tweigeri; Asma Tulbah; Mohmmed Alshabanah; Osama Al Malik
Journal:  World J Clin Oncol       Date:  2016-04-10

2.  Palpable Lumps after Mastectomy: Radiologic-Pathologic Review of Benign and Malignant Masses.

Authors:  Rend Al-Khalili; Ali Alzeer; Giang-Kimthi Nguyen; Erin P Crane; Judy H Song; Janice L Jeon; Michael Nellamattathil; Erini V Makariou; Victoria L Mango
Journal:  Radiographics       Date:  2021-05-14       Impact factor: 6.312

Review 3.  Current view on ductal carcinoma in situ and importance of the margin thresholds: A review.

Authors:  A Van Cleef; S Altintas; M Huizing; K Papadimitriou; P Van Dam; W Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2014

Review 4.  A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Authors:  Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen
Journal:  Int J Cancer       Date:  2019-05-08       Impact factor: 7.396

5.  Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.

Authors:  Nadia Nocera Zachariah; Amrita Basu; Namrata Gautam; Ganesan Ramamoorthi; Krithika N Kodumudi; Nagi B Kumar; Loretta Loftus; Brian J Czerniecki
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

6.  Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.

Authors:  Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin
Journal:  BJS Open       Date:  2022-03-08

7.  MiRNA expression deregulation correlates with the Oncotype DX® DCIS score.

Authors:  Olivier Loudig; Megan I Mitchell; Iddo Z Ben-Dov; Christina Liu; Susan Fineberg
Journal:  Breast Cancer Res       Date:  2022-09-12       Impact factor: 8.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.